The Kratom Knowledge Gap: A Market in Search of Its Data Backbone

ORANGE, CA – June 29, 2026 – In the sprawling, digitally-native marketplace for wellness products, information is the most valuable currency. Yet, for the estimated 15 million Americans who use kratom, a foundational knowledge gap is turning informed choice into a game of chance. A stark new survey released by Kratom Spot, a long-standing online vendor, reveals that only 38% of consumers report fully understanding the kratom strains they purchase. This finding does more than just highlight consumer confusion; it exposes the fragile infrastructure of trust supporting a global market that surpassed $1.3 billion in 2023.

The issue lies in the chasm between marketing narratives and product reality. As the industry rapidly expands beyond traditional powders into concentrated extracts, shots, and gummies, the call for a robust information backbone—one built on data, transparency, and education—has become an existential imperative. “If people do not understand the differences between strains, formats, and product labels, they are not fully equipped to make informed purchasing decisions,” said Patrick Carter, Marketing Director at Kratom Spot, in a statement accompanying the survey. “And policymakers are definitely not equipped to make decisions on banning kratom if they don’t understand the effects, either.”

Decoding the 'Strain' Myth

The root of the confusion begins with the industry's lexicon. Consumers navigate a dizzying array of products labeled with names like ‘Red Bali,’ ‘Green Maeng Da,’ or ‘White Borneo.’ This terminology implies that, like in the cannabis market, these are genetically distinct strains, each cultivated to produce a consistent and unique profile of effects. The reality is far more nuanced and less scientific. These names typically refer not to botanical varieties, but to a combination of the leaf’s vein color, the geographic region of origin, and post-harvest processing techniques like drying methods.

While experienced users report discernible differences, this marketing-driven classification system creates a significant information fog for the majority. Without a standardized framework, the effects attributed to a ‘Red Vein’ kratom from one vendor may not align with those from another. This inconsistency is a critical failure in the information network that connects producer to consumer. The survey’s finding that nearly two-thirds of users are navigating this landscape with an incomplete map underscores the consequences. As one public health researcher noted, the perceived differences in effects are often more influenced by marketing and anecdotal reports than by verifiable chemical distinctions, placing the burden of discovery entirely on the user.

Building an Infrastructure of Trust

Operating in the gray space of federal regulation, the kratom industry has been forced to construct its own infrastructure of trust. The U.S. Food and Drug Administration (FDA) maintains a skeptical stance, having never approved kratom for medical use and periodically issuing warnings against vendors making unsubstantiated health claims. The agency has previously flagged products, including some from Kratom Spot, for containing heavy metals or for being marketed with unapproved therapeutic claims, casting a long shadow of regulatory risk over the entire sector.

In response, the industry’s most proactive players have rallied around a self-governance model championed by the American Kratom Association (AKA). The AKA’s Good Manufacturing Practice (GMP) program serves as the closest thing to a quality-control backbone, requiring certified vendors to undergo third-party audits and rigorous lab testing for alkaloid content, heavy metals, and microbial contaminants. However, this network is far from universal. Of an estimated 10,000 vendors in the U.S., fewer than 150 currently hold this certification, signaling a vast, unregulated frontier where quality and transparency are not guaranteed.

The core of this trust infrastructure is the Certificate of Analysis (COA)—a lab report that provides the ground truth for a given product batch. Here, the digital backbone of the industry reveals its fractures. While AKA-certified vendors like Kratom Spot conduct third-party testing, the accessibility of that data varies widely. Some vendors require customers to email a request for a COA, which may or may not be specific to the batch they purchased. In contrast, transparency leaders in the space are embedding QR codes on every package, linking customers directly to a batch-specific report detailing precise alkaloid percentages and contaminant screenings. This practice transforms the product from an opaque commodity into a verifiable, data-backed good.

The Data Imperative in a Murky Market

The consequences of this information asymmetry are not merely academic. The proliferation of highly concentrated kratom extracts and edibles amplifies the risk of improper dosing, and the knowledge gap can lead directly to negative experiences. One recent survey found that 67% of adverse events related to kratom extracts were the result of users taking an incorrect dose—a clear indicator that the educational component is failing. As Carter of Kratom Spot noted, the industry needs “clear labeling, accessible educational resources, and responsible communication.”

The path forward depends on a fundamental shift away from the folklore of ‘strain’ names and toward a language of verifiable metrics. The most critical data points for a consumer are not a product’s origin story, but its measured mitragynine and 7-hydroxymitragynine content—the primary alkaloids responsible for its effects. Reputable vendors are increasingly competing on this axis of transparency, publicly disclosing alkaloid percentages and making clean, comprehensive lab reports the centerpiece of their value proposition.

Ultimately, the challenge facing the kratom industry is a microcosm of the trust crisis affecting many emerging digital-first markets. When technology and market demand outpace regulation, the responsibility falls upon the industry itself to build the invisible networks of verification and education that empower consumers and legitimize the market. For kratom, the future hinges not on the potency of its leaves, but on the strength and transparency of its data backbone.